Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D058892:Adenosine Deaminase Inhibitors; D000328:Adult; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism; D002986:Clinical Trials as Topic; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004247:DNA / Q000378:metabolism; D004341:Drug Evaluation; D004357:Drug Synergism; D006801:Humans; D007941:Leukemia P388 / Q000188:drug therapy* / Q000378:metabolism; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051379:Mice; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D015649:Pentostatin; D013936:Thymidine / Q000378:metabolism; D014740:Vidarabine / Q000494:pharmacology*
D058892:Adenosine Deaminase Inhibitors; D003070:Coformycin; D015649:Pentostatin; C010192:9-(2-hydroxy-3-nonyl)adenine; D004247:DNA; D009700:Nucleoside Deaminases; D014740:Vidarabine; D000225:Adenine; D013936:Thymidine